- Home
- VNRX vs TVRD Comparison
VNRX vs TVRD Comparison
Compare VNRX & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VNRX | TVRD |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.2M | 37.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | VNRX | TVRD |
|---|---|---|
| Price | $0.25 | $4.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $2.50 | ★ $51.67 |
| AVG Volume (30 Days) | ★ 2.2M | 139.1K |
| Earning Date | 11-13-2025 | 02-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,472,007.00 | N/A |
| Revenue This Year | $55.98 | N/A |
| Revenue Next Year | $420.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.48 | N/A |
| 52 Week Low | $0.22 | $3.74 |
| 52 Week High | $0.94 | $43.65 |
Technical Indicators
Market Signals| Indicator | VNRX | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 38.95 | 39.72 |
| Support Level | $0.22 | $3.90 |
| Resistance Level | $0.26 | $4.46 |
| Average True Range (ATR) | 0.02 | 0.23 |
| MACD | 0.00 | 0.21 |
| Stochastic Oscillator | 42.29 | 52.70 |
Price Performance
Historical ComparisonAbout VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.